Pfizer Says Litfulo Improves Facial, Total Body Repigmentation in Vitiligo Studies

Data ReadoutpositiveLitfuloPositive

AI Analysis

Summary

Pfizer announced that Litfulo demonstrated improvements in facial and total body repigmentation in vitiligo clinical studies. The positive data supports the drug's therapeutic potential for treating this pigmentation disorder.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Litfulo improved facial and total body repigmentation in vitiligo studies

Importance:6/10

Sentiment:

0.70

vitiligodermatologyrepigmentationclinical_data

Related Companies

$PFE

Read the original article

Published by yahoo_finance on October 2, 2026 4:15 PM

Read Original